摘要
目的探究复方丹参滴丸联合麝香保心丸在不稳定性心绞痛经皮冠状动脉介入治疗后的临床效果。方法纳入2020年10月—2021年9月收治到我院的138例不稳定性心绞痛患者作为研究对象,随机分为对照组(69例)和观察组(69例)。对照组在常规治疗的基础上加用复方丹参滴丸,观察组在对照组的基础上联用麝香保心丸,两组患者连续用药4周。观察患者临床症状改善情况,检测治疗前后血清hs-CRP以及炎性因子水平,并对患者做心绞痛评分及血瘀证评分。结果观察组患者治疗总有效率显著高于对照组(P<0.05),差异有统计学意义;治疗后两组患者血清hs-CRP水平及相关炎性因子水平均有所下降,且观察组治疗后血清hs-CRP、IL-6、TNF-α、sCD40L水平显著低于对照组治疗后水平(P<0.05),差异有统计学意义;治疗后观察组心绞痛评分和血瘀证评分显著低于对照组治疗后评分(P<0.05)。结论复方丹参滴丸联合麝香保心丸在不稳定性心绞痛患者经皮冠状动脉介入治疗后能够显著改善临床治疗效果,降低血清hs-CRP及炎性因子水平,提高患者的临床诊疗效果,值得推广。
Objective To explore the clinical effect of Compound Danshen Dropping Pill(复方丹参滴丸)combined with Shexiang Baoxin Pill(麝香保心丸)after percutaneous coronary intervention in unstable angina pectoris.Methods A total of 138 patients with unstable angina pectoris admitted to the hospital from October 2020 to September 2021 were randomly divided into control group(69 cases)and observation group(69 cases).The control group was treated with Compound Danshen Dropping Pill on the basis of routine treatment,and the observation group was treated with Shexiang Baoxin Pill on the basis of the control group.The patients in the two groups were treated continuously for 4 weeks.The improvement of clinical symptoms was observed,and the levels of serum hypersensitive C-reactive protein(hs-CRP)and inflammatory factors were detected before and after treatment.Results The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the levels of serum hs-CRP and related inflammatory factors in the two groups decreased,and the levels of serum hs-CRP,interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)and the level of sCD40 L in the observation group after treatment in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the scores of angina pectoris and blood stasis syndrome in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Compound Danshen Dropping Pill combined with Shexiang Baoxin Pill can significantly improve the clinical treatment effect,reduce the levels of serum hs-CRP and inflammatory factors,and improve the clinical diagnosis and treatment effect of patients with unstable angina pectoris after percutaneous coronary intervention.It is worthy of further effective promotion.
作者
张蓓
卢晓
ZHANG Bei;LU Xiao(Wuhan Hospital of Integrated Traditional Chinese and Western Medicine,Wuhan 430030,Hubei,China)
出处
《实用中医内科杂志》
2022年第8期132-134,共3页
Journal of Practical Traditional Chinese Internal Medicine
基金
武汉市卫生健康委科技计划(WZ14A06)。
关键词
复方丹参滴丸
麝香保心丸
不稳定性心绞痛
HS-CRP
炎性因子
Compound Danshen Dropping Pill(复方丹参滴丸)
Shexiang Baoxin Pill(麝香保心丸)
unstable angina pectoris
hs-CRP
inflammatory factor
